No Data
No Data
<Today's individual materials> TKP, Jelly BG, Kawachi Pharmaceutical, Succeed ETC (Announced on the 23rd)
▽ TKP <3479.T>, the number of facilities usable under the Shareholder benefit system has been expanded to 17 by adding 7 new facilities. ▽ Jelly BG <3070.T> has formed a business partnership with ANAP <3189.T>. ▽ Kawachi Drugs <2664.T> reports a decline in consolidated financial results for the cumulative third quarter of the fiscal year ending March 2025 (from March 16, 2024, to December 15, 2024). ▽ Succeed <9256.T> has made 'School AI', a platform focused on Mainland Education utilizing generative Artificial Intelligence (AI), a subsidiary. ▽ Ghee
Jelly beans, globbing, and others.
<277A> Groving Stock Splits, 5 shares to 1 share <3070> Jelly Beans ANAP <3189> entered into a business partnership <3479> TKP expanded its Shareholder benefits program <9256> Succeed acquired shares of Mingaku, which specializes in the educational sector, and is involved in the planning, development, and Operation of the generative AI platform 'School AI' and made it a subsidiary.
Stocks that moved the previous day part 2: Kyogoku Unyu, GMO Ad Partners, Ise Chemical, ETC.
Stock Name <Code> Closing Price on the 26th ⇒ Change from Previous Day Fuji HD <4676> 1767.5 -91.5 Concern over the ripple effect of magazine articles. Kioxia HD <285A> 1590 -7425 Favorable return selling after significant rebound in recent days. Seed <7743> 551 -36 Continuing the declining trend after recent sharp price increase. Istyle <3660> 448 -19 Pressured by short-term funds' profit-taking selling. Appier Group <4180> 1479 -21 A sense of completion in the rebound.
Emerging Markets Stock Digest: Synbio Pharmaceuticals continues to fall, Business Coach temporarily hits the upper limit.
＜4263＞ Susmed 582 +7 rebound. It was announced that the operation of a clinical trial system (SUSMED SDS) utilizing Blockchain Technology was started in a doctor-led clinical trial at the National Center of Neurology and Psychiatry. This clinical trial targets patients with myalgic encephalomyelitis/chronic fatigue syndrome, aiming to verify the efficacy and safety of Rituximab. Utilizing SUSMED SDS, it aims to reduce monitoring tasks and improve the quality and reliability of the data obtained.
Stocks that moved or were traded in the first half of the session.
*J. Front Retailing <3086> 2150 +1569 - The November period surpassed consensus expectations. *Sekisui Chemical <4204> 2647.5 +193.5 - Reports on the mass production of perovskite Solar Cells have circulated. *Mitsukoshi Isetan <3099> 2696.5 +176.5 - Rising along with J. Front’s favorable Earnings Reports. *Pan Pacific International Holdings <7532> 4250 +231 - European securities have raised the Target Price projections. *Unitika <3103> 148 +7
Hot Stocks Digest (Morning Session): Sekisui Chemical, J. Front, Towns, ETC.
Sekisui Chemical Co. (<4204>): 2,647.5 yen (+193.5 yen) showing significant continued growth. It has been reported that the company will invest approximately 310 billion yen in the mass production of the next-generation Solar Cells "Perovskite Type" and is planning to construct a new factory in Sakai City. Operations are scheduled to commence by 2030, and the production capacity is expected to be around 1 million kW in power generation capacity for the batteries. This seems equivalent to the power generation capacity of one Nuclear Power plant. The government is likely to subsidize about 160 billion yen, which is half of the investment. Expectations for future market expansion are high.